Veristat Strengthens Its Long-Standing Relationship with Aegerion Pharmaceuticals by Establishing a Preferred Provider Agreement

SOUTHBOROUGH, Mass.--()--Veristat, a full service Clinical Research Organization (CRO), announced today the signing of a Preferred Provider Agreement (PPA) with Aegerion Pharmaceuticals Inc. (“Aegerion”), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Veristat has assisted Aegerion with US Food and Drug Administration, EU Market Authorization Application, and Japan Food and Drug Administration submission projects over the past 5 years.

“We feel like a true partner to Aegerion and are eager to continue to deliver quality expertise and services for their marketing applications.”

Veristat will offer Aegerion clinical trial support including statistical consulting, biostatistical analysis, clinical data management, clinical monitoring, SAS programming, clinical protocol and study report writing, project management and the preparation of regulatory submission documents.

“Veristat has been a strong and dedicated collaborative partner and an extension of our project teams,” said Pamela Foulds, MD, Vice President of Clinical Development at Aegerion Pharmaceuticals.

“Veristat is thrilled to progress to this next phase in our working relationship with Aegerion,” stated Barbara Balser, VMD, Chief Scientific Officer at Veristat. “We feel like a true partner to Aegerion and are eager to continue to deliver quality expertise and services for their marketing applications.”

About Veristat:

Veristat is an innovative full-service, science-focused clinical research organization (CRO) with over 20 years of experience in supporting clinical trials and regulatory submissions for pharmaceutical, biotechnology, and medical device companies. Veristat offers comprehensive clinical development services, including biostatistics, statistical programming, medical writing, clinical monitoring, project management and data management, for a single study or an entire clinical program, as well as preparation of integrated summary documents and submission-ready CDISC data for regulatory filings. Due to Veristat’s unwavering commitment to scientific integrity, client focus and exceptional performance, long-lasting client relationships are our hallmark. For more information, please visit www.veristat.com.

Contacts

Veristat
Gillian Dellacioppa, 508-306-6336
Marketing Director
gillian.dellacioppa@veristat.com

Release Summary

Veristat signs a Preferred Provider Agreement (PPA) with Aegerion Pharmaceuticals to provide clinical development and regulatory submission support for rare disease therapies.